Top Markets
Coin of the day
VISEN Pharmaceuticals VISEN Pharmaceuticals

VISEN Pharmaceuticals

2561
Peringkat dalam Saham #16882
VISEN Pharmaceuticals operates as an investment holding company, concentrating... VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
Harga Saham
$2.52
Kapitalisasi Pasar
$274.65M
Perubahan (1 hari)
0.46%
Perubahan (1 tahun)
-56.11%
Negara
CN
Perdagangan VISEN Pharmaceuticals (2561)

Kategori

EPS untuk VISEN Pharmaceuticals (2561)
EPS per 2026 TTM: 0
Menurut laporan keuangan terbaru dan harga saham VISEN Pharmaceuticals, EPS perusahaan saat ini (TTM) adalah 0. Pada akhir 2026, perusahaan memiliki EPS sebesar 0 sama dengan EPS tahun 2026 sebesar 0.
Riwayat EPS untuk VISEN Pharmaceuticals dari 2026 hingga 2026
EPS di akhir setiap tahun
Tahun EPS Mengubah
Tidak cukup data untuk tanggal yang disediakan.
EPS untuk perusahaan sejenis atau pesaing